Ameritas Investment Partners’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,117
| Closed | -$4.96K | – | 3298 |
|
|
2024
Q1 | $4.96K | Hold |
3,117
| – | – | ﹤0.01% | 2951 |
|
|
2023
Q4 | $2.68K | Hold |
3,117
| – | – | ﹤0.01% | 3047 |
|
|
2023
Q3 | $3.33K | Hold |
3,117
| – | – | ﹤0.01% | 3036 |
|
|
2023
Q2 | $8.07K | Hold |
3,117
| – | – | ﹤0.01% | 2964 |
|
|
2023
Q1 | $12.7K | Hold |
3,117
| – | – | ﹤0.01% | 2636 |
|
|
2022
Q4 | $15.6K | Hold |
3,117
| – | – | ﹤0.01% | 2661 |
|
|
2022
Q3 | $40K | Buy |
3,117
+618
| +25% | +$9.36K | ﹤0.01% | 2148 |
|
|
2022
Q2 | $32K | Hold |
2,499
| – | – | ﹤0.01% | 2286 |
|
|
2022
Q1 | $38K | Hold |
2,499
| – | – | ﹤0.01% | 2229 |
|
|
2021
Q4 | $44K | Hold |
2,499
| – | – | ﹤0.01% | 2207 |
|
|
2021
Q3 | $53K | Buy |
2,499
+400
| +19% | +$8.81K | ﹤0.01% | 2119 |
|
|
2021
Q2 | $41K | Hold |
2,099
| – | – | ﹤0.01% | 2325 |
|
|
2021
Q1 | $61K | Hold |
2,099
| – | – | ﹤0.01% | 1971 |
|
|
2020
Q4 | $64K | Hold |
2,099
| – | – | ﹤0.01% | 1839 |
|
|
2020
Q3 | $33K | Hold |
2,099
| – | – | ﹤0.01% | 2102 |
|
|
2020
Q2 | $41K | Hold |
2,099
| – | – | ﹤0.01% | 1957 |
|
|
2020
Q1 | $26K | Hold |
2,099
| – | – | ﹤0.01% | 2036 |
|
|
2019
Q4 | $39K | Buy |
2,099
+1,506
| +254% | +$22K | ﹤0.01% | 2065 |
|
|
2019
Q3 | $8K | Hold |
593
| – | – | ﹤0.01% | 2827 |
|
|
2019
Q2 | $9K | Buy |
+593
| New | +$8.68K | ﹤0.01% | 2839 |
|
Ameritas Investment Partners's NGM Position: Q2 2024 in Review
Ameritas Investment Partners sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 3,117 shares — an estimated $4.96K sold.
Ameritas Investment Partners first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $64K in Q4 2020. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Ameritas Investment Partners reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Ameritas Investment Partners sold 3,117 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $4.96K.
- Ameritas Investment Partners first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- Ameritas Investment Partners's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $64K in Q4 2020.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Ameritas Investment Partners's 13F filing for Q2 2024, filed 13 Aug 2024.